ANI Pharmaceuticals (NASDAQ: ANIP) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.
This table compares ANI Pharmaceuticals and Ligand Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares ANI Pharmaceuticals and Ligand Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ANI Pharmaceuticals||$128.62 million||6.56||$3.93 million||$0.63||114.94|
|Ligand Pharmaceuticals||$108.97 million||27.51||-$1.63 million||$0.69||205.93|
ANI Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
55.1% of ANI Pharmaceuticals shares are owned by institutional investors. 31.8% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 8.3% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a summary of current ratings and target prices for ANI Pharmaceuticals and Ligand Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ANI Pharmaceuticals currently has a consensus price target of $71.00, suggesting a potential downside of 1.95%. Ligand Pharmaceuticals has a consensus price target of $147.80, suggesting a potential upside of 4.02%. Given Ligand Pharmaceuticals’ higher possible upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than ANI Pharmaceuticals.
Risk & Volatility
ANI Pharmaceuticals has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
ANI Pharmaceuticals beats Ligand Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.